^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lestaurtinib (CEP-701)

    i
    Other names: CEP-701, CEP-701, KT-5555, SPM-924
    Company:
    Kyowa Kirin, Teva
    Drug class:
    JAK2 inhibitor, FLT3 inhibitor, STAT5 inhibitor
    Related drugs:
    Apply
    N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma (NCT00084422)
    Phase 1
    New Approaches to Neuroblastoma Therapy Consortium
    Completed
    Last update posted :
    04/10/2023
    Initiation :
    08/01/2003
    Primary completion :
    09/01/2009
    Completion :
    02/01/2011
    NTRK2
    |
    lestaurtinib (CEP-701)
    Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00469859)
    Phase 1/2
    Children's Oncology Group
    Completed
    Last update posted :
    03/15/2017
    Initiation :
    06/01/2007
    Primary completion :
    03/01/2010
    Completion :
    03/01/2010
    FLT3
    |
    cytarabine • idarubicin hydrochloride • lestaurtinib (CEP-701)
    Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) (NCT00079482)
    Phase 2
    Cephalon
    Completed
    Last update posted :
    07/21/2016
    Initiation :
    10/01/2003
    Primary completion :
    03/01/2009
    Completion :
    01/01/2010
    FLT3
    |
    cytarabine • etoposide IV • mitoxantrone • lestaurtinib (CEP-701)
    Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia (NCT01150669)
    Phase N/A
    Children's Oncology Group
    Completed
    Last update posted :
    05/18/2016
    Initiation :
    07/01/2010
    Primary completion :
    05/01/2016
    Completion :
    05/01/2016
    FLT3 • ANXA5
    |
    lestaurtinib (CEP-701)